Australia's most trusted
source of pharma news
Friday, 26 June 2026
Posted 25 June 2026 PM
Arrotex has lost its CEO but the deals keep coming with an exclusive agreement to bring first-to-market prescription eye drops to Australia to treat presbyopia, this time with group CEO Dennis Bastas doing the talking.
Vizz eye drops, 1.44% Aceclidine, is the only product of US-based Lenz, and is sold in the US for $115 (US$79) a month. Arrotex has nabbed the exclusive commercialisation rights in Australia and New Zealand to treat presbyopia.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.